Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Survival of melanoma patients treated with targeted therapy and immunotherapy after systematic upfront control of brain metastases by radiosurgery.

European journal of cancer (Oxford, England : 1990) - 1 Oct 2017

Gaudy-Marqueste C, Dussouil A S, Carron R, Troin L, Malissen N, Loundou A, Monestier S, Mallet S, Richard M A, Régis J M, Grob J J

Abstract excerpt

BACKGROUND: Targeted therapy (TT) and immunotherapies (ITs) have dramatically improved survival in metastatic melanoma (MM). However, their efficacy on brain metastasis (BM) remains limited and poorly documented. PATIENTS AND METHODS: Retrospective cohort of consecutive MM patients (pts) with BMs, all systematically upfront treated by Gamma-Knife (GK) at first BM and retreated in case of new BMs, from 2010 to...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies
Share to Chemotherapy, Adjuvant

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Immunotherapy

Share to MAP Kinase Kinase Kinases

Share to Molecular Targeted Therapy

Share to Programmed Cell Death 1 Receptor

Share to Proportional Hazards Models

Share to Radiosurgery

Source

Identifiers

PMID: 28783540
DOI: 10.1016/j.ejca.2017.07.017

Genes

BRAF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Survival of melanoma patients treated with targeted therapy and immunotherapy after systematic upfront control of brain metastases by radiosurgery.PMID 28783540Read ↗

The Prognostic Value of BRAF, C-KIT, and NRAS Mutations in Melanoma Patients With Brain Metastases.Semantic proximity Read ↗

Treatment Sequencing and Clinical Outcomes in BRAF-Positive and BRAF-Negative Unresectable and Metastatic Melanoma Patients Treated with New Systemic Therapies in Routine Practice.Semantic proximity Read ↗

Systemic therapies for melanoma brain metastases: which drug for whom and when?Semantic proximity Read ↗

Melanoma Brain Metastasis, Prognostic Factors, and Survival Outcomes After First Metastatic Line Therapy: A Monocentric Retrospective Study.Semantic proximity Read ↗

Survival of melanoma patients with brain metastases treated with ipilimumab and stereotactic radiosurgery.Semantic proximity Read ↗

Melanoma brain metastasis: the impact of stereotactic radiosurgery, BRAF mutational status, and targeted and/or immune-based therapies on treatment outcome.Semantic proximity Read ↗

Multidisciplinary approach to brain metastasis from melanoma: the emerging role of systemic therapies.Semantic proximity Read ↗

Efficiency and tolerance of second-line triple BRAF inhibitor/MEK inhibitor/anti-PD1 combined therapy in BRAF mutated melanoma patients with central nervous system metastases occurring during first-line combined targeted therapy: a real-life survey.Semantic proximity Read ↗

Recommended first-line management of brain metastases from melanoma: A multicenter survey of clinical practice.Semantic proximity Read ↗

Clinical and radiological response of BRAF inhibition and MEK inhibition in patients with brain metastases from BRAF-mutated melanoma.Semantic proximity Read ↗

Clinical efficacy of immune checkpoint inhibitors in patients with brain metastases.Semantic proximity Read ↗

Upfront targeted therapy for symptomatic melanoma brain metastases: paradigm changing?Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.